PL2897939T3 - Pochodne amidu kwasu benzoimidazolo-karboksylowego do leczenia chorób metabolicznych i sercowo-naczyniowych - Google Patents
Pochodne amidu kwasu benzoimidazolo-karboksylowego do leczenia chorób metabolicznych i sercowo-naczyniowychInfo
- Publication number
- PL2897939T3 PL2897939T3 PL13763087T PL13763087T PL2897939T3 PL 2897939 T3 PL2897939 T3 PL 2897939T3 PL 13763087 T PL13763087 T PL 13763087T PL 13763087 T PL13763087 T PL 13763087T PL 2897939 T3 PL2897939 T3 PL 2897939T3
- Authority
- PL
- Poland
- Prior art keywords
- benzoimidazole
- carboxylic acid
- acid amide
- cardiovascular diseases
- amide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306142 | 2012-09-21 | ||
| EP13763087.7A EP2897939B1 (en) | 2012-09-21 | 2013-09-19 | Benzoimidazole-carboxylic acid amide derivatives for treating metabolic or cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2897939T3 true PL2897939T3 (pl) | 2017-08-31 |
Family
ID=47010450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13763087T PL2897939T3 (pl) | 2012-09-21 | 2013-09-19 | Pochodne amidu kwasu benzoimidazolo-karboksylowego do leczenia chorób metabolicznych i sercowo-naczyniowych |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9156796B2 (pl) |
| EP (1) | EP2897939B1 (pl) |
| JP (1) | JP6186438B2 (pl) |
| KR (1) | KR20150058284A (pl) |
| CN (1) | CN104640846A (pl) |
| AU (1) | AU2013320323B2 (pl) |
| BR (1) | BR112015005972A2 (pl) |
| CA (1) | CA2885272A1 (pl) |
| CY (1) | CY1118973T1 (pl) |
| DK (1) | DK2897939T3 (pl) |
| ES (1) | ES2623528T3 (pl) |
| HR (1) | HRP20170628T1 (pl) |
| HU (1) | HUE031733T2 (pl) |
| IL (1) | IL237212A (pl) |
| LT (1) | LT2897939T (pl) |
| MX (1) | MX2015003653A (pl) |
| PL (1) | PL2897939T3 (pl) |
| PT (1) | PT2897939T (pl) |
| RU (1) | RU2015114772A (pl) |
| SG (1) | SG11201501051UA (pl) |
| SI (1) | SI2897939T1 (pl) |
| WO (1) | WO2014044738A1 (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143120A (ja) * | 1997-07-28 | 1999-02-16 | Ishikawajima Harima Heavy Ind Co Ltd | 容器の後処理装置 |
| PT3102576T (pt) | 2014-02-03 | 2019-07-17 | Vitae Pharmaceuticals Inc | Inibidores de dihidropirrolopiridina de ror-gama |
| EP3134079A4 (en) * | 2014-04-23 | 2017-12-20 | X-RX Discovery, Inc. | Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases |
| MX387055B (es) * | 2014-06-06 | 2025-03-19 | Res Triangle Inst | Agonistas del receptor de apelina (apj) y usos de los mismos. |
| GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2016176473A1 (en) | 2015-04-28 | 2016-11-03 | Sanford-Burnham Medical Researc Institute | Apelin receptor agonists and methods of use thereof |
| KR102653667B1 (ko) | 2015-05-20 | 2024-04-03 | 암젠 인크 | Apj 수용체의 트라이아졸 작용제 |
| HK1247915B (en) * | 2015-06-03 | 2020-04-24 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| ES2856931T3 (es) * | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| US10392347B2 (en) * | 2015-10-14 | 2019-08-27 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as APJ agonists |
| JP6914257B2 (ja) | 2015-11-20 | 2021-08-04 | ヴァイティー ファーマシューティカルズ，エルエルシー | Ｒｏｒ−ガンマのモジュレーター |
| US10626096B2 (en) | 2015-11-24 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Azole derivatives as apelin receptor agonist |
| BR112018010720A8 (pt) * | 2015-12-04 | 2019-02-26 | Bristol Myers Squibb Co | agonistas do receptor de apelina e métodos de uso |
| MA43417A (fr) | 2015-12-09 | 2018-10-17 | Res Triangle Inst | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations |
| AU2016372048B2 (en) * | 2015-12-16 | 2021-02-04 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| WO2017157332A1 (zh) * | 2016-03-18 | 2017-09-21 | 江苏恒瑞医药股份有限公司 | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| CN114507217A (zh) | 2016-10-12 | 2022-05-17 | 三角研究所 | 杂环爱帕琳肽受体(apj)激动剂及其用途 |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| AU2018298193A1 (en) * | 2017-07-06 | 2020-01-02 | Jiangsu Hengrui Medicine Co., Ltd. | Indole-formamide derivative, preparation method therefor and use thereof in medicine |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| BR112020001246A2 (pt) | 2017-07-24 | 2020-07-21 | Vitae Pharmaceuticals, Llc | inibidores de rory |
| EP3664806B1 (en) | 2017-08-09 | 2025-04-30 | Sanford Burnham Prebys Medical Discovery Institute | 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| JP2021512151A (ja) | 2018-01-23 | 2021-05-13 | ネクストキュア インコーポレイテッド | Ｂ７−ｈ４抗体およびその使用方法 |
| US11724997B2 (en) | 2018-03-01 | 2023-08-15 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| US11858916B2 (en) * | 2018-06-15 | 2024-01-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| ES2976515T3 (es) | 2018-10-05 | 2024-08-02 | Annapurna Bio Inc | Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| IL305789A (en) * | 2021-03-10 | 2023-11-01 | Vincere Biosciences Inc | USP30 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2720199A (en) * | 1998-02-03 | 1999-08-23 | Boehringer Ingelheim Pharma Kg | Five-membered, benzo-condensed heterocycles used as antithrombotic agents |
| US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
| AU2002347022A1 (en) * | 2001-12-20 | 2003-07-09 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
| SE0301699D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| EP1903052A3 (en) * | 2006-07-28 | 2008-04-02 | Faust Pharmaceuticals SA | APJ receptor ligands and uses thereof |
| WO2008153701A1 (en) | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
-
2013
- 2013-09-19 HR HRP20170628TT patent/HRP20170628T1/hr unknown
- 2013-09-19 SG SG11201501051UA patent/SG11201501051UA/en unknown
- 2013-09-19 US US14/031,427 patent/US9156796B2/en not_active Expired - Fee Related
- 2013-09-19 WO PCT/EP2013/069432 patent/WO2014044738A1/en not_active Ceased
- 2013-09-19 PL PL13763087T patent/PL2897939T3/pl unknown
- 2013-09-19 RU RU2015114772A patent/RU2015114772A/ru not_active Application Discontinuation
- 2013-09-19 CA CA2885272A patent/CA2885272A1/en not_active Abandoned
- 2013-09-19 ES ES13763087.7T patent/ES2623528T3/es active Active
- 2013-09-19 HU HUE13763087A patent/HUE031733T2/en unknown
- 2013-09-19 MX MX2015003653A patent/MX2015003653A/es unknown
- 2013-09-19 EP EP13763087.7A patent/EP2897939B1/en not_active Not-in-force
- 2013-09-19 KR KR1020157009028A patent/KR20150058284A/ko not_active Withdrawn
- 2013-09-19 PT PT137630877T patent/PT2897939T/pt unknown
- 2013-09-19 JP JP2015532401A patent/JP6186438B2/ja not_active Expired - Fee Related
- 2013-09-19 BR BR112015005972A patent/BR112015005972A2/pt not_active Application Discontinuation
- 2013-09-19 SI SI201330620A patent/SI2897939T1/sl unknown
- 2013-09-19 AU AU2013320323A patent/AU2013320323B2/en not_active Ceased
- 2013-09-19 CN CN201380048540.0A patent/CN104640846A/zh active Pending
- 2013-09-19 DK DK13763087.7T patent/DK2897939T3/en active
- 2013-09-19 LT LTEP13763087.7T patent/LT2897939T/lt unknown
-
2015
- 2015-02-12 IL IL237212A patent/IL237212A/en not_active IP Right Cessation
-
2017
- 2017-04-25 CY CY20171100461T patent/CY1118973T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013320323A1 (en) | 2015-04-16 |
| SI2897939T1 (sl) | 2017-05-31 |
| EP2897939A1 (en) | 2015-07-29 |
| DK2897939T3 (en) | 2017-05-08 |
| CN104640846A (zh) | 2015-05-20 |
| KR20150058284A (ko) | 2015-05-28 |
| SG11201501051UA (en) | 2015-03-30 |
| PT2897939T (pt) | 2017-05-04 |
| US9156796B2 (en) | 2015-10-13 |
| AU2013320323B2 (en) | 2018-03-15 |
| BR112015005972A2 (pt) | 2017-07-04 |
| IL237212A0 (en) | 2015-04-30 |
| HUE031733T2 (en) | 2017-07-28 |
| US20140094450A1 (en) | 2014-04-03 |
| ES2623528T3 (es) | 2017-07-11 |
| LT2897939T (lt) | 2017-05-10 |
| CY1118973T1 (el) | 2018-01-10 |
| IL237212A (en) | 2016-10-31 |
| EP2897939B1 (en) | 2017-02-01 |
| HRP20170628T1 (hr) | 2017-06-30 |
| MX2015003653A (es) | 2015-09-25 |
| RU2015114772A (ru) | 2016-11-10 |
| JP2015532916A (ja) | 2015-11-16 |
| JP6186438B2 (ja) | 2017-08-23 |
| CA2885272A1 (en) | 2014-03-27 |
| WO2014044738A1 (en) | 2014-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2897939T (lt) | Benzimidazolo karboksirūgšties amido dariniai metabolinių arba širdies ir kraujagyslių ligų gydymui | |
| KR102297388B9 (ko) | 대사장애를 치료하기 위한 아커만시아의 용도 | |
| SG11201503646TA (en) | Esterification of 2,5-furan-dicarboxylic acid | |
| ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
| IL233333A0 (en) | Compositions and methods for the treatment of metabolic disorders | |
| SG11201507496UA (en) | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases | |
| IL235425B (en) | History of lysine-glutamic acid di-peptide | |
| PL2828208T3 (pl) | Aktywowanie kwasu organicznego za pomocą nadsiarczanu | |
| AP4063A (en) | Dimethyl-benzoic acid compounds | |
| IL236965B (en) | Derivatives of 5-aminolevulinic acid and uses thereof | |
| EP2875122A4 (en) | PROCESSES FOR PRODUCING METABOLIC LINE PRODUCTS | |
| IL235317A0 (en) | A compound for the treatment of metabolic disorders | |
| IL235802A0 (en) | A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid | |
| IL250725B (en) | Difluorolactam formulations for ep4-mediated bone-related conditions and diseases | |
| ZA201400918B (en) | Pyrrolidine-3-ylacetic acid derivative | |
| IL238592A0 (en) | Methods for treating liver diseases | |
| PL2931696T3 (pl) | Ciągły sposób otrzymywania kwasu (S)-2-acetyloksypropionowego | |
| EP2857010A4 (en) | Dihydroorotic-DEHYDROGENASEHEMMER | |
| ZA201504658B (en) | Cinnamic acid amide derivative | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| GB201207359D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201207363D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201219092D0 (en) | Treatment of cardiovascular disease | |
| EP2865747A4 (en) | 4,6-HEXADECADIENE-2,4-DICARBOXYLIC ACID DERIVATIVE | |
| GB201106154D0 (en) | Compounds for the treatment of metabolic disorders |